Vericel Corp: insider trades · United States · SEC (Form 4)

About Vericel Corp

Vericel Corp. (NASDAQ:VCEL) is a United States-based commercial-stage biotechnology and regenerative medicine company listed on the NASDAQ market in the United States. Headquartered in Cambridge, Massachusetts, United States, the company has evolved from its origins as Aastrom Biosciences into a focused specialty biologics platform centered on autologous cell therapies for highly specialized, high-value indications. The modern Vericel story took shape after the 2014 rebranding, when the company shifted toward marketed products and away from a pure development-stage profile. ([investors.vcel.com](https://investors.vcel.com/news-releases/news-release-details/aastrom-biosciences-changes-name-vericel-corporation?utm_source=openai)) Vericel’s business is organized around three core products. MACI is the flagship franchise and is used for the repair of symptomatic cartilage defects in the knee through an autologous cell therapy approach. Epicel is a permanent skin replacement product for patients with deep dermal or full-thickness burns, giving Vericel a niche position in severe burn care. NexoBrid, licensed for North American commercial rights, extends the portfolio into enzymatic debridement for severe thermal burns. Together, these products place Vericel in a highly specialized segment with meaningful regulatory barriers, complex manufacturing requirements, and strong relationships with orthopedic and burn centers. ([vcel.com](https://www.vcel.com/about/?utm_source=openai)) From a competitive standpoint, Vericel stands out because very few companies have comparable exposure to both sports-medicine cartilage repair and severe burn treatment. The company emphasizes its autologous-cell-therapy expertise, its deep commercial infrastructure in the United States, and its manufacturing know-how as key differentiators. A major strategic development is the new manufacturing and corporate headquarters facility in Burlington, Massachusetts, which was built to expand cell-therapy capacity and support long-term growth for MACI and Epicel. Recent company communications indicate the facility is complete and commercial manufacturing is expected to begin in 2026. ([investors.vcel.com](https://investors.vcel.com/news-releases/news-release-details/vericel-announces-plans-new-state-art-cell-therapy-manufacturing?utm_source=openai)) For investors, the appeal lies in MACI’s commercial visibility, the relatively defensible nature of Vericel’s niche markets, and the operational upside from additional manufacturing capacity. The company’s 2025 updates highlighted strong revenue momentum and improved profitability, supported by MACI and increasing contribution from NexoBrid in burn care. As a NASDAQ-listed U.S. healthcare small cap, Vericel offers a concentrated product mix, a clear strategic focus, and a primarily domestic commercial footprint. ([investors.vcel.com](https://investors.vcel.com/news-releases/news-release-details/vericel-reports-first-quarter-2025-financial-results-and-raises?utm_source=openai))